Latest Biotech News

Thermo Fisher unveiled the Orbitrap Astral Zoom mass spectrometer, raising scan rates and adding ion pre‑accumulation to boost throughput and sensitivity for proteomics and metabolomics. The...

Researchers from MIT and Recursion released Boltz‑2, an open‑source model that improved speed and accuracy for predicting binding affinities—delivering results in seconds and ranking top at CASP16...

A study in the Journal of Translational Medicine described an ultra‑broad hybrid-capture targeted NGS approach to detect circulating pathogen-derived cell‑free DNA in blood plasma. The method...

George Tidmarsh, director of the FDA’s Center for Drug Evaluation and Research (CDER), has been placed on administrative leave, according to multiple reports. Tidmarsh leads the agency office that...

Intellia Therapeutics paused dosing and screening in two Phase III programs for its in vivo CRISPR candidate nexiguran ziclumeran (nex‑z) after a patient experienced severe liver injury; the FDA...

Thermo Fisher Scientific agreed to acquire Clario for approximately $9 billion, adding software that collects, manages, and analyzes clinical trial endpoint data to Thermo Fisher’s biopharma...

Pfizer filed suit in Delaware’s Court of Chancery seeking to enforce its merger agreement with Metsera and to block a rival proposal from Novo Nordisk. Pfizer alleges Metsera’s board and Novo...

Moderna is confronting a deep business reset after Covid‑era revenues shrank and anticipated mRNA follow‑ons failed to materialize at scale. Internal and external reporting details layoffs, cost...

Thermo Fisher launched the Orbitrap Astral Zoom mass spectrometer, upgrading scan rate and ion pre‑accumulation to boost throughput and sensitivity for large‑scale proteomics. The company says the...

Researchers at MIT, with Recursion, released Boltz‑2 — an open‑source model that markedly improved binding‑affinity prediction speed and accuracy and topped CASP16 affinity benchmarks. Boltz‑2...

AdventHealth’s chief digital officer, David Oakley, said AI and connected data platforms will push healthcare from population‑level segmentation toward individualized 'segments of one.' Oakley...

Widespread H5N1 outbreaks and occasional human spillovers have renewed interest in bacteriophage approaches for secondary bacterial infections and as vaccine platforms. Public health trackers...

GEN’s analysis identified roughly $230 billion in annual sales tied to drugs whose key U.S. patents expire between 2026 and 2029; the top 20 alone generated about $176 billion last year. The...

Thermo Fisher Scientific agreed to acquire Clario for about $9 billion, moving to integrate Clario’s clinical-trial software that captures, manages and analyzes endpoint data with Thermo Fisher’s...

Pfizer filed suit in Delaware against Metsera’s board and Novo Nordisk after Novo launched a counterproposal for obesity developer Metsera, seeking to block Metsera from terminating an earlier...

Moderna’s post‑pandemic strategy has faltered as Covid vaccine revenues decline and promised mRNA pipeline successes have yet to materialize, according to an expansive industry account. The...

Rising HPAI (H5N1) spillovers and mounting agricultural losses have renewed interest in bacteriophage therapies, researchers and public‑health agencies report. The U.S. CDC and USDA briefings show...

An analysis identified the top 20 blockbuster drugs facing key U.S. patent expirations between 2026 and 2029, representing roughly $176.4 billion in annual sales. The report links looming...

Thermo Fisher rolled out the Orbitrap Astral Zoom mass spectrometer to boost throughput and sensitivity for proteomics and metabolomics studies, aiming to scale multiomics in clinical and...

New large quantitative models are changing structure‑based small‑molecule discovery: MIT and Recursion’s Boltz‑2 demonstrated rapid, accurate binding‑affinity predictions, while companies like...